Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non-Small-Cell Lung Cancer

被引：79

作者：

Laurie, Scott A. ^{[1
]}

Goss, Glenwood D. ^{[1
]}

机构：

[1] Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON K1H 8L6, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 08期

关键词：

RANDOMIZED PHASE-II; PREVIOUSLY TREATED PATIENTS; 1ST-LINE TAXANE/CARBOPLATIN; MOLECULAR PREDICTORS; ELDERLY-PATIENTS; SUPPORTIVE CARE; ERBB RECEPTORS; GEFITINIB PLUS; ERLOTINIB; CHEMOTHERAPY;

D O I：

10.1200/JCO.2012.43.4522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Worldwide, the majority of patients with advanced non-small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors of this pathway, and data from randomized trials suggest that some of these wild-type patients will derive a modest benefit from these agents. Although the detection of an activating mutation predicts for a greater likelihood of response and longer progression-free survival from an EGFR tyrosine kinase inhibitor, currently there are no biomarkers that consistently and reproducibly predict for lack of benefit in wild-type patients. Several strategies to increase the efficacy of these inhibitors in wild-type NSCLC are the subject of ongoing investigations. J Clin Oncol 31:1061-1069. (C) 2013 by American Society of Clinical Oncology

引用

页码：1061 / 1069

页数：9

共 67 条

[1] Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21 [J].

Addison, Christina L. ;

Ding, Keyue ;

Zhao, Huijun ;

Le Maitre, Aurelie ;

Goss, Glenwood D. ;

Seymour, Lesley ;

Tsao, Ming-Sound ;

Shepherd, Frances A. ;

Bradbury, Penelope A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) :5247-5256

[2]

[Anonymous], J CLIN ONCOL

[3] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer [J].

Brugger, Wolfram ;

Triller, Nadja ;

Blasinska-Morawiec, Maria ;

Curescu, Stefan ;

Sakalauskas, Raimundas ;

Manikhas, Georgy Moiseevich ;

Mazieres, Julien ;

Whittom, Renaud ;

Ward, Carol ;

Mayne, Karen ;

Trunzer, Kerstin ;

Cappuzzo, Federico .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4113-4120

[4] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[5] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[6] Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older [J].

Chen, Yuh-Min ;

Tsai, Chun-Ming ;

Fan, Wen-Chien ;

Shih, Jen-Fu ;

Liu, Shih-Hao ;

Wu, Chieh-Hung ;

Chou, Teh-Ying ;

Lee, Yu-Chin ;

Perng, Reury-Perng ;

Whang-Peng, Jacqueline .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) :412-418

[7] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Miliauskas, Skaidrius ;

Grigorescu, Alexandru Calin ;

Hillenbach, Carina ;

Johannsdottir, Hrefna Kristin ;

Klughammer, Barbara ;

Esteban Gonzalez, Emilio .

LANCET ONCOLOGY, 2012, 13 (03) :300-308

[8] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [J].

Ciuleanu, Tudor ;

Brodowicz, Thomas ;

Zielinski, Christoph ;

Kim, Joo Hang ;

Krzakowski, Maciej ;

Laack, Eckart ;

Wu, Yi-Long ;

Bover, Isabel ;

Begbie, Stephen ;

Tzekova, Valentina ;

Cucevic, Branka ;

Pereira, Jose Rodrigues ;

Yang, Sung Hyun ;

Madhavan, Jayaprakash ;

Sugarman, Katherine P. ;

Peterson, Patrick ;

John, William J. ;

Krejcy, Kurt ;

Belani, Chandra P. .

LANCET, 2009, 374 (9699) :1432-1440

[9] Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer [J].

Cote, Michele L. ;

Haddad, Ramsi ;

Edwards, David J. ;

Atikukke, Govindaraja ;

Gadgeel, Shirish ;

Soubani, Ayman O. ;

Lonardo, Fulvio ;

Bepler, Gerold ;

Schwartz, Ann G. ;

Ethier, Stephen P. .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) :627-630

[10] Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study [J].

Crino, Lucio ;

Cappuzzo, Federico ;

Zatloukal, Petr ;

Reck, Martin ;

Pesek, Milos ;

Thompson, Joyce C. ;

Ford, Hugo E. R. ;

Hirsch, Fred R. ;

Varella-Garcia, Marileila ;

Ghiorghiu, Serban ;

Duffield, Emma L. ;

Armour, Alison A. ;

Speake, Georgina ;

Cullen, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4253-4260

← 1 2 3 4 5 6 7 →